奥希替尼联合GP方案对非小细胞肺癌患者血清VEGF和MMP-9表达的影响  

Effect of osimertinib combined with GP therapy on expression of serum VEGF and MMP-9 of non-small cell lung cancer patients

作　　者：张敬宝 周晓英 路中[3] 张春玲 ZHANG Jingbao;ZHOU Xiaoying;LU Zhong;ZHANG Chunling(Department of Oncology,Weifang Medical College,Weifang 261053,Shandong,China;Department of Tumor and Hematology,Jiaozhou Hospital,East Hospital Affiliated to Tongji University,Qingdao 266300,Shandong,China;Department of Oncology,the Affiliated Hospital of Weifang Medical University,Weifang 261031,Shandong,China;Department of Respiratory Medicine,Qingdao Central Hospital,Qingdao 266003,Shandong,China)

机构地区：[1]潍坊医学院肿瘤科,山东潍坊261053 [2]同济大学附属东方医院胶州医院肿瘤血液科,山东青岛266300 [3]潍坊医学院附属医院肿瘤科,山东潍坊261031 [4]青岛市中心医院呼吸科,山东青岛266003

出　　处：《贵州医科大学学报》2022年第9期1082-1086,共5页Journal of Guizhou Medical University

基　　金：山东省自然科学基金(2014WS0017)。

摘　　要：目的 探究奥希替尼联合GP方案对非小细胞肺癌(NSCLC)患者血清血管内皮生长因子(VEGF)、基质金属蛋白酶9(MMP-9)表达的影响。方法 NSCLC患者86例随机分为GP组(43例)和联合组(43例),2组患者均给予GP方案治疗,联合组在GP方案治疗基础上给予奥希替尼治疗;分别于治疗前、治疗后3个月时采用酶联免疫吸附法检测NSCLC患者血清VEGF、MMP-9水平,同时采用Karnofsky体能状况评分量表(KPS)评估生存状态、生命质量测定量表第3版(QLQ-C30 V3.0)评估生活质量;于治疗后3个月时评估临床疗效并记录不良反应发生情况。结果 与治疗前比较,2组NSCLC患者治疗后血清VEGF、MMP-9水平均明显降低(P<0.05),且联合组低于GP组(P<0.05);两组NSCLC患者治疗后KPS评分、各项QLQ-C30评分升高(P<0.05),且联合组高于GP组(P<0.05);与GP组疾病控制率(37.21%)比较,联合组疾病控制率(62.79%)升高(P<0.05)。结论 奥希替尼联合GP方案治疗NSCLC患者可有效降低血清VEGF、MMP-9水平,改善患者生活质量及健康状况,效果明确且安全。Objective To investigate the effect of osimertinib combined with GP therapy on the efficacy and expression of serum vascular endothelial growth factor( VEGF) and matrix metalloproteinase 9(MMP-9) of non-small cell lung cancer(NSCLC) patients.Methods A total of86 patients with NSCLC were selected and randomly divided into GP group(43 cases) and combined group(43 cases). Both groups were treated with GP therapy, the combined group was treated with additional oxitinib therapy;serum level of VEGF and MMP-9 were detected by enzyme-linked immunosorbent assay before treatment and 3 months after treatment. Meanwhile, adopting Karnofsky performance status(KPS) scale to evaluate the survival status of both groups, and QLQ-C30 V3. 0 to evaluate the quality of life for both groups;evaluating the clinical efficacy and recording the occurrence of adverse reactions after 3 months of treatment.Results Compared with before treatment, the levels of serum VEGF and MMP-9 in both groups were significantly decreased after treatment(P< 0. 05),and the combined group was lower than that of GP group(P< 0. 05). KPS score and QLQ-C30 scores of both groups increased significantly after treatment(P< 0. 05), and the combined group was higher than that of GP group(P< 0. 05). Compared with the disease control rate of GP group(37. 21%),the disease control rate in the combined group(62. 79%) increased significantly(P< 0. 05).Conclusion Osimertinib combined with GP therapy in the treatment of patients with non-small cell lung cancer could effectively decrease serum VEGF and MMP-9 levels, improve the quality of life and health of patients, and the efficacy was clear and safe.

关 键 词：非小细胞肺癌 GP方案 基质金属蛋白酶9 奥希替尼 血管内皮生长因子 疗效 生活质量 

分 类 号：R734.2[医药卫生—肿瘤]